Q-omics provides the consensus-scored MZT2B profile across patient tissues and cancer cell-line models. MZT2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MZT2B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MZT2B RNA expression shows 19,032 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where MZT2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MZT2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MZT2B survival associations across molecular data types. MZT2B RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MZT2B RNA expression–survival associations across cancer types. High MZT2B expression shows unfavorable associations in KIRP, LIHC, ACC, LUAD, COAD and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MZT2B RNA expression.
This table summarizes MZT2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MZT2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MZT2B shows higher tumor expression in KIRC, KIRP, HNSC, LUSC, LIHC and LUAD. The KIRC box plot shows higher MZT2B RNA expression in tumor versus normal tissue (log2 FC = +1.206, t-test p < 0.001).
This table shows molecular features associated with MZT2B in patient tissues and cancer cell lines. In patient samples, MZT2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MZT2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
